Sabby Management’s Ocera Therapeutics, Inc. OCRX Stock Holding History

Sabby Management’s Portfolio OCRX Stock Details OCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-328,632	Closed	-$690K	–	361
2016 Q4	$690K	Sell	328,632 -71,403	-18%	-$167K	0.04%	171
2016 Q3	$1.06M	Sell	400,035 -24,000	-6%	-$60K	0.04%	180
2016 Q2	$806K	Buy	424,035 +25,000	+6%	+$65.7K	0.04%	177
2016 Q1	$1.17M	Buy	399,035 +13,735	+4%	+$39.2K	0.06%	144
2015 Q4	$1.2M	Sell	385,300 -41,244	-10%	-$141K	0.07%	165
2015 Q3	$1.35M	Buy	426,544 +46,970	+12%	+$181K	0.06%	205
2015 Q2	$1.44M	Buy	379,574 +25,000	+7%	+$95.9K	0.05%	197
2015 Q1	$1.67M	Sell	354,574 -75,371	-18%	-$434K	0.07%	159
2014 Q4	$2.74K	Buy	+429,945	New	+$2.52M	0.09%	103
2014 Q3	–	Sell	-151,358	Closed	-$1.16M	–	323
2014 Q2	$1.16M	Buy	151,358 +90,632	+149%	+$722K	0.05%	137
2014 Q1	$641K	Buy	60,726 +742	+1%	+$10.6K	0.04%	162
2013 Q4	$779K	Buy	+59,984	New	+$560K	0.05%	131

Other funds holding OCRX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Sabby Management's OCRX Position: Q1 2017 in Review

Sabby Management sold out of Ocera Therapeutics, Inc. (OCRX) in Q1 2017, closing a stake of 328,632 shares — an estimated $690K sold.

Sabby Management first reported a position in OCRX in Q4 2013 and held it in 12 quarters. The position peaked at $1.67M in Q1 2015. 26 funds tracked by Wall St. Rank hold OCRX as of Q1 2017.

Sabby Management reported no remaining Ocera Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
Sabby Management sold 328,632 Ocera Therapeutics, Inc. shares in Q1 2017, an estimated $690K.
Sabby Management first reported a position in Ocera Therapeutics, Inc. in Q4 2013 and held it in 12 quarters.
Sabby Management's Ocera Therapeutics, Inc. position peaked at $1.67M in Q1 2015.
26 funds tracked by Wall St. Rank held Ocera Therapeutics, Inc. as of Q1 2017.

Based on Sabby Management's 13F filing for Q1 2017, filed 15 May 2017.